For the first time, a new form of targeted radiotherapy, or PRRT (Peptide Receptor Radio Therapy) using Lutetium-177 octreotate is available in Belgium. Thanks to a long-term endeavour of logistics, processes and national approval issues, this [...]
Belgian based IBA and US investment firm SK Capital Partners have joined forces to create a promising new company, IBA Molecular Imaging. Both sides show great enthusiasm about this partnership and the potential role they will [...]